Modulus Therapeutics

📍 Seattle, United States🗓 Founded 2020👥 13 employees💰 Last funded 2021
Biotechnology Research🌐 modulustherapeutics.com
Website LinkedIn
Modulus is engineering next-generation immune cell therapies, starting with Natural Killer cells rationally designed for the treatment of solid tumors. Modulus’ Convergent Design™ platform combines genetic engineering, machine learning, and high-throughput in vivo screening to systematically converge on optimized cell designs. Modulus is committed to the discovery of cell therapies to treat a broad set of patient populations not currently served by existing treatments and will use its platform to enable partners and develop an internal pipeline of therapeutics.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2020
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Modulus Therapeutics?
Modulus Therapeutics has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Modulus Therapeutics last raise funding?
The most recent investment in Modulus Therapeutics recorded on gritt.io was in 2021.
When was Modulus Therapeutics founded?
Modulus Therapeutics was founded in 2020.
What industry is Modulus Therapeutics in?
Modulus Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Modulus Therapeutics based?
Modulus Therapeutics is headquartered in Seattle, United States.